Update on Long-Term Safety & Efficacy of CTP-543, an Oral JAK Inhibitor, for the Treatment of Alopecia Areata

Time: 10:15 am
day: Day Two


  • CTP-543 was dosed for 24 weeks in three Phase 2 trials; eligible patients subsequently enrolled in a long-term, open-label extension trial with >130 patients treated for more than 1 year.
  • Hair regrowth assessed by SALT has been sustained or improved in the vast majority of patients in the extension study relative to the Phase 2 results
  • Treatment with CTP-543 continues to be generally well tolerated, with a safety profile similar to that observed in Phase 2.